Biotech News
Related news
MXCTMaxCyte2026-04-29 20:05 EST
MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026
MXCTMaxCyte2026-05-12 20:06 EST
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
KRYSKrystal Biotech2026-07-23 21:00 EST
Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026
ABEOAbeona Therapeutics2026-08-06 11:30 EST
Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
TSHATaysha Gene Therapies2026-08-04 20:00 EST
Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11
NTLAIntellia2026-07-30 12:00 EST
Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates
OCGNOcugen2026-07-28 20:01 EST
Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results
NTLAIntellia2026-08-06 11:00 EST
Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
SRPTSarepta Therapeutics2026-08-05 20:05 EST
Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments
CRSPCRISPR Therapeutics2026-08-03 20:15 EST
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
MaxCyte
Cell Engineering Platform MaxCyte provides electroporation systems and services used to engineer cells for research, clinical development, and commercial cell therapies. ExPERT Platform The ExPERT instruments introduce molecules into cells at laboratory through commercial scale while preserving cell viability and function. Strategic...
Recent company news
MXCTMaxCyte2026-07-21 12:05 EST
MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development
MXCTMaxCyte2026-07-15 20:05 EST
MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026
MXCTMaxCyte2026-06-23 13:00 EST
VectorBuilder Partners with MaxCyte® to Advance Clinical-Grade Cell Engineering
MXCTMaxCyte2026-05-12 20:06 EST
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
MXCTMaxCyte2026-04-29 20:05 EST
MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026
Stock data
- Close
- 1.11 USD
- Market cap
- 131.76M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States